纳米药物递送系统在基于化疗的联合治疗中的研究进展

Advances of nanocarrier-based drug delivery system in chemotherapy-based combination therapy

肿瘤是一种病理过程复杂的疾病。大多数肿瘤患者接受化疗和放疗,但这些治疗通常只对部分有效,并产生各种严重的副作用。因此,有必要开发新的治疗策略。联合治疗是目前肿瘤治疗的热点,联合用药引起的多种协同作用是提高抗肿瘤活性的关键。纳米药物递送系统的出现对临床治疗产生了深远的影响。药物的体内递送常不能达到令人满意的治疗效果,而纳米药物递送系统可以实现肿瘤靶向给药,在提高抗肿瘤效果的同时降低药物的毒副作用。本文介绍了多种基于化疗的联合治疗方法,重点阐述了纳米药物递送系统在基于化疗的联合治疗中的运用,并对该领域面临的挑战和未来发展方向进行了展望。

Tumor is a disease with complex pathological process.Most cancer patients receive chemotherapy and radiotherapy,but these treatments are usually only partially efficacious and lead to a variety of serious side effects.Therefore,it is necessary to develop new therapeutic strategies.Combination therapy is a current hot topic in tumor therapy.Multiple synergistic effects elicited by combined drugs are essential in improving antitumor activity.The emergence of nanocarrier-based drug delivery systems(NDDSs)has a profound impact on general clinical treatment.In vivo delivery of drugs sometimes fails to achieve satisfactory therapeutic effects.NDDSs can realize tumor-targeted drug delivery,improve the anti-tumor effect and reduce the toxicity and side effects of drugs.This review introduces a variety of chemotherapy-based combination therapies,focuses on the application of NDDSs in chemotherapy-based combination therapies,and looks forward to the challenges and future development directions in this field.